Bharat Biotech's homegrown COVID-19 vaccine has shown an interim vaccine efficacy of 81% in late-stage clinical trials, the Indian company said on Wednesday.
The interim analysis was based on 43 recorded cases of COVID-19 in the trial of 25,800 participants, conducted in partnership with the Indian government's medical research body.
Thirty-six of the 43 cases were recorded in participants who received a placebo, compared with seven cases in people who were given the Bharat Biotech vaccine, pointing to an efficacy rate of 80.6%, the company said.
India had approved the vaccine, branded COVAXIN, in January without late-stage efficacy data, raising questions about its effectiveness.
India's vaccination drive, currently underway, includes COVAXIN and a vaccine developed by Oxford University and AstraZeneca.
Earlier this week, Indian Prime Minister Narendra Modi was inoculated with the first dose of COVAXIN.
Trump touts $5,000 payout if Republicans win as Vance waits in wings
Search expands after Philippine ferry fire kills five and leaves dozens missing
Trump says Iran war to end after US midterm elections
At least 20 killed in cargo vessel fire at China shipyard, state media reports
US military says it struck vessel in Caribbean, killing 3
At least 14 killed in explosion at weapons depot in Syria
US hits five Iranian oil tankers after attack on Navy ships
UK gives air traffic provider a week to probe outage that halted flights
